Breathe Well Live Well
|
AstraZeneca Buys Synairgen Asthma Drug For $7.25M
BioResearch Online (press release) AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. SNG001 is … |
View full post on asthma – Google News
|
Amgen Posts Positive Phase I Results For Asthma Drug
BioResearch Online (press release) Amgen reported positive results from the Phase I study showing that inhibiting thymic stromal lymphopoietin (TSLP) could be useful in the treatment of asthma. TSLP is a cytokine considered to be a key driver of the allergic inflammation that … Anti-thymic stromal lymphopoietin therapy reduced allergy-induced … |
View full post on asthma – Google News
|
Rigel Assumes Development Responsibility For Inhaled Asthma
BioResearch Online (press release) South San Francisco, CA /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. … |
View full post on asthma – Google News